



Published in final edited form as:

Dev Biol. 2018 September 01; 441(1): 132–145. doi:10.1016/j.ydbio.2018.06.020.

Hedgehog signaling from the Posterior Signaling Center maintains U-shaped expression and a prohemocyte population in *Drosophila*

Rajkumar Baldeosingh^{a,b,1}, Hongjuan Gao^b, Xiaorong Wu^b, and Nancy Fossett^{a,b,*}

^aGraduate Program in Life Sciences, University of Maryland School of Medicine, Baltimore, MD 21201

^bCenter for Vascular and Inflammatory Diseases and the Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Abstract

Hematopoietic progenitor choice between multipotency and differentiation is tightly regulated by intrinsic factors and extrinsic signals from the surrounding microenvironment. The *Drosophila melanogaster* hematopoietic lymph gland has emerged as a powerful tool to investigate mechanisms that regulate hematopoietic progenitor choice *in vivo*. The lymph gland contains progenitor cells, which share key characteristics with mammalian hematopoietic progenitors such as quiescence, multipotency and niche-dependence. The lymph gland is zonally arranged, with progenitors located in medullary zone, differentiating cells in the cortical zone, and the stem cell niche or Posterior Signaling Center (PSC) residing at the base of the medullary zone (MZ). This arrangement facilitates investigations into how signaling from the microenvironment controls progenitor choice. The *Drosophila* Friend of GATA transcriptional regulator, U-shaped, is a conserved hematopoietic regulator. To identify additional novel intrinsic and extrinsic regulators that interface with U-shaped to control hematopoiesis, we conducted an *in vivo* screen for factors that genetically interact with *u-shaped*. Smoothened, a downstream effector of Hedgehog signaling, was one of the factors identified in the screen. Here we report our studies that characterized the relationship between Smoothened and U-shaped. We showed that the PSC and Hedgehog signaling are required for U-shaped expression and that U-shaped is an important intrinsic progenitor regulator. These observations identify a potential link between the progenitor regulatory machinery and extrinsic signals from the PSC. Furthermore, we showed that both Hedgehog signaling and the PSC are required to maintain a subpopulation of progenitors. This led to a delineation of PSC-dependent versus PSC-independent progenitors and provided further evidence that the MZ progenitor population is heterogeneous. Overall, we have identified a

*Corresponding author: University of Maryland, School of Medicine, Center for Vascular and Inflammatory Diseases, Department of Pathology, 800 W. Baltimore Street, Room 215, Baltimore, MD 21201, 410-706-8062. FAX: 410-706-8121. nfossett@som.umaryland.edu.

¹Present address: The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N., Broadway M002 P Baltimore, MD 21231, USA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

connection between a conserved hematopoietic master regulator and a putative stem cell niche, which adds to our understanding of how signals from the microenvironment regulate progenitor multipotency.

Introduction

Hematopoiesis, the life-long production of blood cells from multipotent progenitors, is tightly regulated by intrinsic factors and extrinsic signals from the surrounding microenvironment. A greater appreciation of the mechanisms that control progenitor choice between multipotency and differentiation will increase our understanding of tissue homeostasis and regeneration and how dysregulation of these processes leads to disease.

Drosophila melanogaster has emerged as a powerful model system to investigate mechanisms that drive hematopoietic progenitor choice *in vivo* because key aspects of hematopoiesis are conserved across taxa¹⁻⁷. *Drosophila* has a rudimentary blood system, with three blood cells that develop from a common progenitor and carry out functions associated with the vertebrate myeloid lineages⁸⁻¹⁸. Plasmatocytes are operational macrophages; crystal cells are named for their crystalline inclusion bodies; and lamellocytes, which are rarely observed under steady-state conditions, differentiate in response to wasp parasitization and other forms of stress including increased levels of reactive oxygen species (ROS) and nutritional deprivation¹⁸⁻³⁹. Moreover, the common hematopoietic progenitor or prohemocyte shares key characteristics with mammalian hematopoietic progenitors including quiescence, multipotency and niche-dependence^{18,25,40,40-65}. Similar to vertebrates, *Drosophila* hematopoiesis occurs at multiple sites throughout the life cycle of the organism. During the larval stage, there are two hematopoietic sites: hematopoietic hubs located along the lateral side of the animal beneath the cuticle; and the lymph gland, a bilateral organ that flanks the insect heart^{15,18,22,28,30,32,40,41,44,50,65-76}.

The lymph gland consists of a pair of primary lobes followed by a series of secondary lobes. The primary lobes are divided into three well defined regions or zones. Prohemocytes reside in the inner region, known as the medullary zone (MZ). Differentiating cells are located at the periphery in the cortical zone (CZ). At the base of the primary lobe is the Posterior Signaling Center (PSC), a small group of cells which produce a variety of signals that control blood cell differentiation in the MZ and CZ^{40,41,50}. This zonal arrangement enables one to determine the origin of regulators that control hematopoiesis and assess how the interaction between prohemocytes, differentiating cells and the microenvironment control prohemocyte choice between multipotency and differentiation^{20,40-42,50,59,60,63,64,77,78}. The PSC has been shown to be essential for lamellocyte differentiation in response to wasp parasitization^{21,43,79}. Additionally, the PSC was thought to function as a stem cell niche that maintains the population of undifferentiated prohemocytes during steady-state conditions^{24,40,41,64,80,81}.

Earlier work suggested that Hedgehog (Hh) signaling from the PSC was one of the pathways required to maintain the prohemocyte population^{8,41,45,48,63,64,78,82}. Hh signaling is a conserved pathway that regulates cell proliferation, migration and differentiation during development and organ formation across taxa. The pathway is activated when the Hh ligand

binds to the transmembrane receptor, Patched (Ptc). This suppresses Ptc activity, which activates the G-protein-like receptor, Smoothened (Smo). In *Drosophila*, activated Smo inhibits the proteolysis of Cubitus interruptus (Ci), the *Drosophila* homolog of the mammalian Gli proteins, and full length Ci translocates to the nucleus to regulate gene expression^{83–85}

More recently the role of the PSC as a stem cell niche operating through various signaling components has been called into question by work showing that genetic ablation of the PSC had no effect on prohemocyte number⁴³. On the other hand, the results from this and another study demonstrated that Early B-cell Factor, Collier (Col) is an intrinsic prohemocyte factor that is required to maintain prohemocytes in a multipotent state^{43,58}. These studies suggest that prohemocyte maintenance is controlled by intrinsic regulators that act independently of the PSC. We previously identified another factor that maintains prohemocyte multipotency, the Friend of GATA (FOG) homolog, U-shaped (Ush)⁸⁶. In this study, we show that Ush acts as an intrinsic prohemocyte regulator. FOG proteins bind GATA factors to activate or repress GATA transcriptional activity. GATA:FOG complexes are master regulators that control the differentiation of selected blood cell types across taxa^{87–97}.

To identify additional novel regulators that interface with Ush to control hematopoiesis, we conducted an *in vivo* screen for genes that genetically interact with *ush*. Using this approach, we identified Smo as a factor that acts with Ush to block lamellocyte differentiation. Here we report our studies that characterized the relationship between Smo and Ush. In the process, we demonstrated that the PSC and Hh signaling are required for Ush expression, thereby linking this important intrinsic prohemocyte regulator to extrinsic signals from the PSC. Furthermore, using four different prohemocyte markers (Odd-skipped, E-cadherin, DomeMESO and Collier), we also provide compelling evidence for the notion that the PSC and Hh signaling are required to maintain a subpopulation of prohemocytes during steady-state hematopoiesis. We showed that loss of Hh signaling or PSC ablation results in a significant reduction in prohemocytes marked with Odd-skipped (Odd), E-cadherin or DomeMESO, but not those marked with Collier (Col). Importantly, we showed that the Col-positive population is also Odd-positive, whereas the Odd-positive population consists of both Col-positive and Col-negative cells. Furthermore, the Odd-positive/Col-negative cells appeared to be largely PSC-dependent, while Col-positive cells appeared to be largely PSC-independent. However, PSC ablation also produced a small population of Col-positive cells with substantially reduced levels of Odd expression; a cell type that was not observed in control lymph glands. This suggests that the PSC maintains optimal levels of Odd expression in a subpopulation of Col-positive prohemocytes. Thus, our findings support the notion that the PSC functions as a hematopoietic niche during steady-state hematopoiesis. Overall, we have identified a connection between a conserved hematopoietic master regulator and a putative stem cell niche, which adds to our understanding of how signals from the microenvironment regulate progenitor multipotency.

Materials and Methods

Fly strains

The *w¹¹¹⁸* strain served as the control stock for these studies. The following strains were generous gifts from colleagues: *Tep4-Gal4, hhF4f;Antp-Gal4/TM6B Tb*, *Col-Gal4/CyO GFP, hhF4f-GFP; Pcol85/CyO GFP* and *MSNF9mo-DsRed (MSN-C)* from T. Tokusumi and R. A. Schulz (University of Notre Dame); *UAS-GFP;DomeMESO-GFP,Antp-Gal4, TM6B Tb* from S. Govind (City College of New York); *Domeless-Gal4* from M. Crozatier (University Paul Sabatier); *w p{w⁺, Dome-MESO}BN1* from M. P. Zeidler (University of Sheffield) and J. C. Hombria (Universidad Pablo de Olavide); *UAS-hh* from Xiaoyan Zheng (The George Washington University). The following strains were obtained from the Bloomington Stock Center: *smo³ b¹ pr¹/CyO, w*;P{UAS-smo.5A}2, w¹¹¹⁸; P{UAS-rpr.C}14, y¹ v¹; P{TRiP.JF01804} (UAS-hh^{RNAi}), y¹ v¹; P{TRiP.JF01715} (UAS-ci^{RNAi}), w*; P{UAS-GFP-ptc.WT}2, w*; P{UAS-GFP-ptc.WT}3, the 2L Deficiency Kit (DK2L) and *y¹ sc* v¹; P{TRiP.HMS00492}/TM3, Sb¹ (UAS-hh^{RNAi})*, which was the alternate strain used in these studies to confirm the results obtained with *UAS-hh^{RNAi}*. *UAS-u-shaped^{RNAi}* transformant number 104102 was obtained from the Vienna Drosophila RNAi Center. The following stocks have been previously described: *y w^{67c23}, ush^{vx22}/CyO y⁺, y w^{67c23}, ush^{R24}/CyO y⁺, y w^{67c23}, UAS-ush^{86,98}*. The *yw; ush^{vx22}, MSN-C/CyO y⁺* was created using standard recombination procedures.*

Screen for factors that genetically interact with *ush*

The *yw; ush^{vx22}, MSN-C/CyO y⁺* stock enabled us to rapidly screen for genes that genetically interact with *ush* to block lamellocyte differentiation. The *MSN-C* lamellocyte marker⁹⁹ was used to identify larvae with an increase in circulating lamellocytes using fluorescence microscopy. *MSN-C* is also constitutively active in larval muscle and serves as a marker for larvae that carry the *ush^{vx22}, MSN-C* chromosome. The *yw; ush^{vx22}, MSN-C/CyO y⁺* stock was crossed to each of the 100 large multi-gene deficiencies that map to Chromosome 2L, which produced *ush/Df(2L)* trans-heterozygotes. However, we could not score the deficiency that uncovers *ush*, as *ush* homozygotes are embryonic lethal and *ush* maps to between 21D1 and 21E2 on chromosome 2L. Scoring was carried out on late third-instar wandering larvae, which were cultured at 23°C. Larvae were placed on a slide with a drop of PBS and observed under fluorescent microscopy using a Zeiss Axioplan microscope.

Gene expression analyses

Gene expression analyses were conducted using lymph glands from mid-third instar larvae (collected 96 to 114 hours after egg laying). As indicated in specific experiments, gene expression analyses were also conducted using lymph glands from late-third instar larvae (collected 120 to 144 hours after egg laying). All control and experimental samples were age-matched and cultured on standard media at 23°C. The UAS/Gal4 binary system¹⁰⁰ was used to express transgenes in a tissue-restricted manner and in these experiments, larvae were shifted to 25°C 48 hours after egg laying. Where possible, for each UAS/Gal4 combination we tested two independent PSC or MZ drivers to show that knockdown or over expression of the transgene in question produced the same phenotype. However, with *UAS-ush* or *UAS-rpr* only the *Col-Gal4* driver was used to express PSC because *Antp-Gal4* driven

ush or *rpr* animals die before gene expression can be assessed. Likewise, the *Dome-Gal4* driven *UAS-smo^{DN}* animals die before hematopoiesis can be assessed, so the *Tep-Gal4* driver was used to express *UAS-smo^{DN}* in the MZ. Controls for these experiments included the Gal4 drivers crossed to *w¹¹¹⁸* mates. Variability across experiments was inevitable, including lymph gland size, due to the fact that these studies were conducted over a considerable period of time by different co-authors. Thus, each experiment was run with an age matched control and we sampled at least 18 primary lymph gland lobes consisting of at least 9 control and 9 experimental samples.

Immunofluorescence

The dissection and fixation of larval lymph glands were performed as previously described⁸⁶. Rabbit anti-Odd was a generous gift from J. Skeath (Washington University School of Medicine)¹⁰¹, and used at a 1:4,000 dilution. Mouse anti-Nimrod (PI) and mouse anti-Attila (LI)¹² were generous gifts from I. Ando (Biological Research Center of the Hungarian Academy of Sciences) and used at a 1:50 dilution. Rabbit anti-prophenoloxidase A1 (anti-ProPO) was a generous gift from F. C. Kafatos (EMBL)¹⁰² and used at a 1:100 dilution. Mouse anti-Collier (Col) antibody was a generous gift from M. Crozatier (University Paul Sabatier)²⁴ and was used at a 1:150 dilution. Rabbit anti-U-shaped was used at a 1:4,000 dilution⁸⁶. Note, we occasionally observed reduced expression in some MZ cells compared to presumptive CZ cells. This could reflect downregulation of Ush to permit MZ cell differentiation, or alternatively, cases where the antibody did not fully penetrate the compacted cellular arrangement of the MZ.

Mouse anti- β -galactosidase was obtained from Promega and used at a 1:2,000 dilution. Rabbit anti-GFP was obtained from Invitrogen and used at a 1:4,000 dilution. Rat anti-E-cadherin and mouse anti-Smo, anti-Antennapedia (Antp), and anti-GFP, were obtained from the Developmental Studies Hybridoma Bank and used at a concentration of 10 pg/ml. Alexafluor-555, or -488-conjugated secondary antibodies directed against rabbit, rat or mouse (Invitrogen) were used at a 1:2,000 dilution.

Fluorescence was captured, analyzed and recorded using Olympus confocal microscopy or Zeiss Axioplan optics. Different biological endpoints were measured including densitometric mean values, the percentage of specific cell types (percentage marker-positive cells) and the area comprising the MZ marker expression domain. Densitometric mean values were measured to determine whether the expression level of the protein in question was significantly different in response to an altered genotype. The percentage of marker-positive cells was measured to determine whether the number of a specific cell type was significantly increased or decreased by an altered genotype. The area comprising the MZ was measured to determine if a specific MZ marker expression domain changed in response to an altered genotype. This latter method was used primarily in cases where counting the number of MZ marker-positive cells is not feasible, such as E-cadherin positive cells. The relative expression was determined from the densitometric mean values calculated for fluorescent antibody staining using Zeiss Axiovision or ImageJ software as previously described^{47,103,104}. The size of the MZ zone was determined by measuring the area of Odd- or E-cadherin-expressing cells and statistical significance was evaluated using the Student's

t-test. Blood cell counts were determined using ImageJ and the percentage was determined by dividing the number of cells expressing a particular protein and by the number of Dapi-expressing nuclei. The statistical significance was evaluated using the Student's t-test. In our hands, control lymph glands have an average of 1 lamellocyte per lymph gland lobe. However, lamellocytes can form large aggregates making it difficult to obtain accurate cell counts. For this reason, we scored primary lymph gland lobes positive for increased lamellocyte differentiation when aggregates were greater than 300 μm^2 or more than 5 individual lamellocytes were visible, as previously described⁴⁷ When comparing 2 samples, statistical significance was evaluated using increased differentiation as a categorical variable for experimental and control samples in 2x2 contingency tables and P values were calculated using Fisher's Exact test. When comparing 3 samples, 2x3 contingency tables were used and P values were calculated using Chi-square test.

Results

Smo maintains Ush protein expression and genetically interacts with *ush* to block lamellocyte differentiation

A number of GATA:FOG co-regulators have been identified; however, the intrinsic and extrinsic signaling networks that interact with GATA:FOG complexes to control hematopoiesis are largely unknown¹⁰⁵. To begin to identify novel intrinsic and extrinsic FOG interacting factors, we conducted an *in vivo* screen for genes that genetically interact with the *Drosophila* FOG homolog, *ush*, to block lamellocyte differentiation. To accomplish this goal, we constructed the *yw; ush^{vx22}, MSN-C/CyO y⁺* stock. *MSN-C* is a marker for lamellocytes⁹⁹, which was used to rapidly identify larvae with an increase in circulating lamellocytes. The screen was conducted by crossing the *yw; ush^{vx22}, MSN-C/CyO y⁺* stock to each of the 100 large multi-gene deficiencies that map to Chromosome 2L, producing *ush/Df(2L)* trans-heterozygotes. However, we could not score the deficiency that uncovers *ush*, as *ush* homozygotes are embryonic lethal and *ush* maps to between 21D1 and 21E2 on chromosome 2L. In our hands, increased lamellocyte differentiation in *ush* hypomorphic (*ush^{vx22/tr24}*) populations ranges from 70% to 100% penetrance (Gao and Fossett unpublished). To minimize false positives, we *a priori* set a minimum 40% penetrance level for lamellocyte differentiation in trans-heterozygotes. While this is less than that observed for *ush* hypomorphs, it was significantly greater than the 6.7% (2 out of 30) observed for negative controls.

Of the 100 deficiencies tested, 21 scored positive in the first pass. We re-tested 9 and confirmed that these genetically interact with *ush* to block lamellocyte differentiation (Baldeosingh and Fossett, unpublished observations). We then tested individual genes that map to the 9 positive deficiencies. One of the deficiencies (*Df(2L)ED19*) uncovered the gene that encodes Smo. We then showed that *smo* genetically interacts with *ush* to block lamellocyte differentiation in the lymph gland. This was accomplished by demonstrating that *ush/smo* double heterozygotes exhibited a significant increase in the number of lymph gland lobes with increased lamellocyte differentiation compared to animals that were singularly heterozygous for either *ush* or *smo* (Figure 1, A–D).

Next, we conducted epistatic analyses to determine the relationship between Smo and Ush during hematopoiesis. Previous work by Tokusumi et al. showed that Ush acts with the GATA factor, Serpent (Srp) to repress Hh expression⁶³. Given that Smo is a downstream effector of Hh signaling, we first tested the possibility that Ush also regulates Smo expression. However, loss of Ush function had no effect on the level of Smo expression (Figure 1, E–G). We then tested if Smo regulated Ush expression. Using the *Tep-Gal4* driver to express a dominant negative form of Smo (Smo^{DN}) in prohemocytes, we showed that loss of Smo function resulted in a statistically significant reduction in Ush expression levels (Figure 1, H–J). Thus, Smo is required for Ush expression, however Ush is not required for Smo expression.

Hh signaling maintains Ush expression levels

Previous studies have suggested that Hh signaling from the PSC maintains prohemocytes^{41,63}.

However, the results of two recent studies have indicated that the prohemocyte population is not regulated by Hh signaling^{43,58}, and indeed, does not require any information from the PSC, as ablation of these cells has no effect on the number of DomeMESO-positive or Col-positive prohemocytes⁴³. Ush is expressed in prohemocytes⁸⁶ and these conflicting reports prompted us to ask if Smo regulates Ush expression through a non-canonical signaling pathway, or alternatively, if Ush expression is indeed maintained by Hh signaling from the PSC. To distinguish between these possibilities, we tested if altering the expression of several Hh signaling pathway members reduced Ush expression levels.

We observed that knockdown of Hh in the PSC resulted in a significant reduction in Ush expression levels (Figure 2 A,B,I). Knockdown of Hh was achieved using *Antp-Gal4* to drive *UAS-hh^{RNAi}* in the PSC. Ptc is a negative regulator of Hh signaling and *Tep-Gal4* driven over-expression of Ptc in prohemocytes also resulted in a significant reduction in the level of Ush expression (Figure 2 C,D,I). Ci is a downstream effector of Hh signaling. Using *Tep-Gal4*, we expressed *UAS-ci^{RNAi}* in prohemocytes and observed that knockdown of Ci significantly reduced the level of Ush expression (Figure 2 E,F,I). We confirmed these results using additional UAS/Gal4 strains. We used another *UAS-hh^{RNAi}* allele to knockdown Hh in the PSC. We also used alternate Gal4 drivers including *Col-Gal4* and *Dome-Gal4*, to express UAS-transgenes in the PSC and MZ, respectively. Under these conditions we again showed that disruption of Hh signaling significantly reduced Ush expression (Supplementary Figure 1).

hh gene expression in the PSC is upregulated by Srp⁶³. In contrast, Ush is not expressed in the PSC^{50,86} and mis-expressing Ush in this tissue blocks *hh* enhancer activity⁶³, presumably by binding Srp and converting it from an activator to a repressor. We confirmed that mis-expressing Ush blocks *hh* enhancer activity, but does not reduce the number of PSC cells (Supplementary Figure 2). Furthermore, we also showed that mis-expressing Ush in the PSC significantly reduced endogenous Ush expression (Figure 2 G,H,I). These results are consistent with the hypothesis that loss of canonical Hh signaling results in loss of Ush expression. Moreover, we consistently observed that disruption of Hh signaling in either the PSC or MZ resulted in a significant reduction in Ush expression throughout the lymph

gland, including in the CZ (Figures 1 and 2 and Supplementary Figure 2). Perhaps precocious activation of the differentiation pathway sets up a reinforcing feedback loop that further represses Ush expression in both the MZ and the differentiating cells of the CZ. In support of this hypothesis, we have previously shown that Ush expression is downregulated in a subset of plasmatocytes, crystal cells and lamellocytes⁸⁶.

Hh signaling is required to block hemocyte differentiation

The observation that Hh signaling maintains Ush expression is in line with previous studies showing that loss of either *ush* expression or Hh signaling results in increased numbers of crystal cells and plasmatocytes^{41,58,63,86}. Previous studies achieved loss of Hh signaling using either a *hh* temperature sensitive (*ts*) allele or by knocking down the *hh* gene activator, Srp, in the PSC^{41,58,63}. Thus, knockdown of Hh in the PSC using *Antp-Gal4* to express *UAS-hh^{RNAi}* should phenocopy the results obtained with the *hh ts* allele and Srp knockdown, that is increased numbers of plasmatocytes and crystal cells. Indeed, we observed that lymph glands with *Antp-Gal4* driven *UAS-hh^{RNAi}* had a statistically significant increase in the numbers of crystal cells (Figure 3 A–C) and plasmatocytes (Figure 3 E–F) compared to controls. Together, these studies indicate that Hh signals from the PSC limit the differentiation of crystal cells and plasmatocytes.

Ush is required to block lamellocyte differentiation^{86,106}. Furthermore, our new findings show that *ush* genetically interacts with *smo* to block lamellocyte differentiation. These observations suggested that Hh signaling blocks lamellocyte differentiation. To test this hypothesis, we disrupted Hh signaling by mis-expressing Ush in the PSC. Under these conditions, we observed a significant increase in the number of lymph gland lobes with increased lamellocyte differentiation (Figure 3 G,H,J). Furthermore, co-expressing Hh and Ush in the PSC rescued the Ush mis-expression phenotype, significantly reducing the number of lymph gland lobes exhibiting lamellocyte differentiation compared to mis-expressing Ush alone (Figure 3 G–J). Collectively, these data provide strong support for the hypothesis that Hh signaling blocks lamellocyte differentiation, which is also consistent with a previous study that showed loss of Smo function in the MZ also increased the number of lamellocytes¹⁰⁷.

Ush functions in the MZ to maintain Odd-positive and E-cadherin-positive prohemocytes

Previous studies have identified Odd and E-cadherin as prohemocyte markers^{50,103,104}. Our work has shown that over-expressing Ush in the MZ increased the number of Odd-positive prohemocytes, whereas systemic loss of Ush function results in the loss of Odd-positive prohemocytes and a significant reduction in the E-cadherin expression domain^{47,86,103,104}. Collectively, these observations support the hypothesis that Ush functions in the MZ to maintain the prohemocyte population. To provide additional support for this hypothesis, we used the *Tep-Gal4* driver to express *UAS-ush^{RNAi}* in the MZ and observed a significant reduction in both the percentage of Odd-positive prohemocytes and the E-cadherin expression domain (Figure 4). We also used an alternate MZ-restricted driver, *Dome-Gal4*, to knockdown Ush and showed that under these conditions the percentage of Odd-positive prohemocytes was again significantly reduced (Supplementary Figure 3). Thus, these data show that Ush functions in the MZ to maintain a prohemocyte population.

Hh signaling is required to maintain a subpopulation of prohemocytes

Given that Hh signaling is required to maintain Ush expression levels and that Ush functions in the MZ to maintain the Odd-positive prohemocyte pool, we then tested if Hh signaling is also required to maintain the Odd-positive prohemocyte population. Knockdown of Hh in the PSC using *Antp-Gal4* driven *UAS-hh^{RNAi}* resulted in a statistically significant reduction in the percentage of Odd-positive prohemocytes (Figure 5 A,B,G). This result was confirmed using the *Col-Gal4* driver to express an alternate *UAS-hh^{NAI}* allele in the PSC (Supplementary Figure 4 A–C). Likewise, disrupting Hh signaling by mis-expressing Ush in the PSC significantly reduced the percentage of Odd-positive prohemocytes (Figure 5 C,D,G). Knockdown of Ci in the MZ also significantly reduced the percentage of Odd-positive prohemocytes (Figure 5 E–G). Moreover, the Odd expression domain was significantly reduced in lymph glands with *Tep-Gal4* driving *UAS-Smo^{DN}* compared to controls (Supplementary Figure 4 D–F). Thus, loss of canonical Hh signaling led to a significant reduction in Odd-positive prohemocytes.

Our findings that Hh signaling maintains Odd-positive prohemocytes is in contrast to a recent study showing that the PSC is not required to maintain prohemocytes marked with either DomeMESO or Col⁴³. We considered that the Odd-positive prohemocyte population may be distinct from that of the DomeMESO- and Col-positive population. To test this hypothesis, we first determined if Odd, DomeMESO, and Col are expressed in different prohemocyte populations. To compare the Odd and DomeMESO expression domains, we used two different fly strains carrying two different versions of the DomeMESO prohemocyte marker: 1) the cytoplasmic marker, DomeMESO- β -galactosidase (DomeMESO- β gal) and 2) the nuclear marker, DomeMESO-GFP. Lymph glands from each of these two strains were analyzed using immuno-fluorescence to determine if Odd was co-expressed with β -gal and/or GFP. We observed that the Odd expression domain largely overlapped that of both DomeMESO reporters (Supplementary Figure 5 A-A''', B-B'''). However, we did observe a small number of cells with either predominately Odd expression (Odd^{high}/DomeMESO^{low}) or predominately DomeMESO expression (Odd^{low}/DomeMESO^{High}). Compare the insets from Supplementary Figure 5A'' with A''' and Supplementary Figure 5 B'' with B'''.

Next, we compared the Odd and Col expression domains by testing if Odd was co-expressed with Col in lymph glands from *w¹¹¹⁸* larvae (Supplementary Figure 5 C-C'''). Co-localization studies showed that the Col-positive population was also Odd-positive, but the Odd-positive population was heterogeneous with both Col-positive and Col-negative cells. Indeed, all of the Col-positive cells appeared to express high levels of Odd (Col^{High}/Odd^{High}); however, none of the Col-positive cells appeared to have low levels of Odd expression (Col^{High}/Odd^{low}). On the other hand, Col expression was not detected in approximately 36% of the Odd-positive cells (Col^{neg}/Odd^{High}). Compare the insets from Supplementary Figure 5C'', C''' and C''\ Thus, the Odd-positive population includes a majority (~64%) of Col-positive cells (Col^{High}/Odd^{High}) with a considerable minority (~36%) of Col-negative cells (Col^{neg}/Odd^{High}). Furthermore, approximately 30% of the Col^{neg}/Odd^{High} minority (~11% of the total Odd-positive population) was located in a region that may include the CZ or perhaps the border region between the MZ and CZ. Compare the panels from Supplementary

Figure 5 C', C'' and C''' Overall, the results from these co-localization analyses are consistent with an earlier study that demonstrated heterogeneity within the prohemocyte population¹⁰⁸.

We then tested the effect of loss of Hh signaling on the population of DomeMESO-positive and Col-positive cells. When we knocked down Hh in the PSC using *Antp-Gal4 {UAS-GFP; DomeMESO-GFP, Antp-Gal4}* to drive *UAS-hh^{RNAi}*, we observed a significant reduction in the number of DomeMESO-GFP expressing cells (Figure 5, H–J). We also observed GFP expression in the PSC, which resulted from *Antp-Gal4* driving *UAS-GFP* in addition to *UAS-hh^{RNAi}*. We confirmed that DomeMESO positive cells were maintained by Hh signaling by showing that when *Col-Gal4* was used to drive an alternate *UAS-hh^{RNAi}* construct in the PSC, β gal expression was significantly reduced (Supplementary Figure 4 G–I). We also disrupted Hh signaling by over-expressing Ush in the PSC and observed that the level of DomeMESO- β gal was significantly reduced (Figure 5 K–M). Conversely, knock down of Hh did not reduce the number of Col-positive cells (Figure 5 N–P), which is consistent with previous findings that show Hh signaling from the PSC is not required to maintain the Col-positive prohemocyte population^{43,58}. Collectively, these results suggest that Hh signaling is required to maintain Odd-positive and DomeMESO-positive prohemocytes, but not Col-positive prohemocytes.

The PSC is required to maintain a subpopulation of prohemocytes

Previous studies have shown that ablation of the PSC has no effect on Col-positive prohemocytes⁴³. Consistent with this observation, our current studies and those from another laboratory⁵⁸ show that loss of Hh signaling from the PSC has no effect on the Col-positive prohemocyte population. In contrast, here we showed that Odd-positive and DomeMESO-positive prohemocytes are reduced when Hh signaling is disrupted. Together, these observations suggest that the MZ contains both PSC-dependent and PSC-independent prohemocytes. To test this hypothesis, we determined if ablating the PSC would alter the expression of Ush and the prohemocyte markers, Odd, E-cadherin, DomeMESO and Col. We used *Col-Gal4* driven *UAS-reaper (rpr)* to ablate the PSC according to the method of Benmimoun et al.⁴³. This resulted in a complete loss of Antp marked PSC cells (Supplementary Figure 6) confirming that the PSC was indeed ablated. Under these conditions, we observed that Ush expression was significantly reduced (Figure 6 A–C). Likewise, the number of Odd-positive cells and the E-cadherin expression domain was also significantly reduced (Figure 6 D–I). We also observed a significant reduction in DomeMESO-positive cells in lymph glands with the PSC ablated (Figure 6 J–L). Conversely, PSC ablation did not significantly reduce the percentage of Col-positive prohemocytes, consistent with the results reported by Benmimoun et al.⁴³. Collectively, our findings support the hypothesis that the MZ contains both PSC-dependent and PSC-independent prohemocytes.

Our new data indicate that the PSC is required to maintain the full complement of Odd-positive, but not Col-positive, prohemocytes. Given that the Odd-positive population includes both Col-positive and Col-negative prohemocytes (Figure 7 A-A'''; Supplementary Figure 5C-C'''), we asked whether the population of Col^{High}/Odd^{High} prohemocytes was

PSC-independent, while the Col^{neg}/Odd^{High} population was PSC-dependent. To address this question, we assayed for Odd and Col co-expression in lymph glands with PSC ablation. Under these conditions, we again observed a statistically significant reduction in the percentage of Odd-positive cells, but no significant change in the percentage of Col-positive cells (Figure 7). Furthermore, the number of Odd-positive cells that remained after PSC ablation was not statistically different from the number of Col-positive cells in either control or PSC ablated lymph glands (Figure 7C). These data suggest that PSC ablation reduces the number of Col^{neg}/Odd^{High} positive prohemocytes, whereas Col-positive prohemocytes are resistant to the effects of PSC ablation. This supports the hypothesis that Col^{neg}/Odd^{High} prohemocytes are largely PSC-dependent, while Col-positive prohemocytes appeared to be largely PSC-independent. However, some of the Col-positive cells exhibited substantially reduced levels of Odd expression (Col^{High}/Odd^{low}; compare insets in Figure 7 B'-B''') in PSC ablated lymph glands. This Col^{High}/Odd^{low} cell type was not observed in either *w¹¹¹⁸* or *Col-Gal4/+* controls (Figure 7 A'-A'''; Supplementary Figure 5C'-C'''). This suggests that the PSC maintains optimal levels of Odd expression in a subset of Col-positive prohemocytes. We observed that Odd was also co-expressed with Col in the PSC (Figure 7 A-A'). However, the level of Odd expression appears to be similar in the MZ and PSC, whereas Col expression is clearly greater in the PSC than in the MZ.

Discussion

The original hypothesis that the PSC functions as a niche from which multiple pathways, including Hh, signal to the MZ to maintain prohemocytes in multipotent state was based on evaluating the hematopoietic function of Col⁴¹. Col is expressed in the PSC and systemic loss of Col function resulted in loss of the prohemocyte population⁴¹. However, more recent work has shown that Col also functions in MZ and loss of Col in this zone, rather than in the PSC, leads to loss of prohemocytes^{43,58}. The role of the PSC in maintaining prohemocyte multipotency was further challenged by work showing that genetic ablation of the PSC had no effect on prohemocyte number⁴³. This also cast doubt on whether Hh, or any other signaling pathway that originates from the PSC, maintains the prohemocyte population. Furthermore, the conclusion that Hh signaling maintains the prohemocyte population was based on studies showing that loss of Hh signaling led to increased numbers of terminally differentiated plasmacytes and crystal cells rather than direct assessment of prohemocyte marker expression⁴¹. Loss of Hh signaling does lead to a reduction in the MZ marker, Ptc⁶³. However, the *ptc* gene is upregulated by Hh signaling¹⁰⁹, leaving unanswered the question of whether Hh signaling maintains the prohemocyte population.

Our new findings provide compelling evidence that the PSC and Hh signaling are required to maintain a subpopulation of prohemocytes during steady-state hematopoiesis. In this study, we directly assessed the prohemocyte population using four different prohemocyte markers, Odd, E-cadherin, DomeMESO and Col. We showed that loss of Hh signaling or PSC ablation results in a significant reduction in prohemocytes marked with Odd and DomeMESO and a significant reduction in the level of DomeMESO and E-cadherin expression. However, consistent with previously published work, we did not see a statistically significant reduction in the number of Col-expressing cells under either condition^{43,58}. Importantly, we showed that the Odd-positive prohemocyte population

consists of both Col-positive (Col^{high}/Odd^{high}) and Col-negative (Col^{neg}/Odd^{high}) cells. Furthermore, Col^{neg}/Odd^{high} cells appear to be largely PSC-dependent, while Col^{high}/Odd^{high} prohemocytes appear to be largely PSC-independent. Nevertheless, PSC ablation also produced some Col-positive cells with substantially reduced levels of Odd expression (Col^{high}/Odd^{low}); a cell type not observed in control lymph glands. This suggests that the PSC maintains optimal levels of Odd expression in some of the Col-positive prohemocytes. Furthermore, the possibility remains that loss of the PSC can affect the transcriptome in a subpopulation of Col-positive prohemocytes by reducing the expression level of the transcription factor, Odd. Overall, our findings support the notion that the PSC functions as a hematopoietic niche during steady-state hematopoiesis.

We speculate that PSC-dependent and PSC-independent prohemocytes might fill two different roles during hematopoiesis. Col-positive, PSC-independent prohemocytes may be resistant to extrinsic signals and regulated primarily by intrinsic signals. This strategy would maintain a pool of undifferentiated cells that are capable of self-renewal and are protected against progenitor exhaustion during steady state hematopoiesis. On the other hand, PSC-dependent prohemocytes would be extrinsically regulated and poised to respond to normal differentiation signals. These new findings may serve as a foundation for studies designed to delve deeper into the underlying mechanisms by which prohemocytes are maintained in a multipotent state. Ultimately, such studies may provide insights into how human hematopoietic stem cells (HSCs) can be generated and maintained indefinitely *ex vivo*. In this regard, recent reports showed that *ex vivo* reprogramming of mammalian tissues requires as yet uncharacterized extracellular cues in order to obtain fully functional HSCs^{110–112}.

A recent report demonstrated that Dpp signaling from the PSC is required during the early first instar to maintain a transient Notch-positive prohemocyte precursor. Loss of Dpp signaling during the first larval instar reduced the number of prohemocyte precursors, leading to a dramatic reduction in lymph gland size by the third larval instar⁴⁵. In contrast, the method of Benmimoun et al. achieves maximum PSC ablation later in development, during the second larval instar⁴³. Under these conditions, PSC ablation did not affect the size of the third instar lymph gland. This supports the hypothesis of Dey et al.⁴⁵, which states that Dpp signaling from the PSC is required in first larval instar to maintain Notch-positive prohemocyte precursors; however, Dpp is dispensable for lymph gland growth from the second larval instar onward. Furthermore, loss of Dpp did not alter the relative number of CZ and MZ cells⁴⁵. Thus, Dpp controls early precursor cell number but does not regulate cell fate. In contrast, we showed that Hh is required to maintain MZ Odd-positive prohemocytes and limit CZ cells, including plasmatocytes, crystal cells and lamellocytes. Thus, Hh signaling promotes prohemocyte multipotency while limiting differentiation. This is reminiscent of the role of aberrant Hh signaling in hematopoietic malignancies. In this case, Hh signaling from adjacent stromal or tumor cells are thought to maintain cancer stem cells by upregulating pluripotency factors¹¹³.

Our findings show that DomeMESO-positive prohemocytes were reduced in response to disrupted Hh signaling or PSC ablation, which is in contrast to previous reports^{43,58}. Nevertheless, our results and conclusions are supported by the following aspects of our

experimental approach. First, we obtained the same results using two different DomeMESO strains and with multiple methods designed to disrupt Hh signaling, including PSC ablation. Additionally, our methods are comparable to the ones used in those previous studies^{43,58} given that we, like they, observed that the number of Col-positive cells were unchanged in response to Hh disruption or PSC ablation. While we have no explanation for the differences obtained with the DomeMESO marker across laboratories, we have no doubt that continued characterization of the lymph gland system will uncover the reasons for these inter-lab differences, which may be of considerable importance in understanding the mechanism of progenitor multipotency.

Notably, there is a paucity of information about how extrinsic signaling pathways interface with GATA:FOG complexes during mammalian hematopoiesis¹⁰⁵. However, studies in *Drosophila* have identified new interactions between signaling pathways and the GATA:FOG (Srp:Ush) complex. For example, a previous study showed that Ush acts with Srp to block *hh* gene expression⁶³. This finding, coupled with our new data, points to a potential negative feedback loop in which Hh signaling from the PSC upregulates Ush in the MZ, which then binds Srp to limit *hh* expression. Notably, abnormal Hh signaling promotes tumor development and hematological malignancies^{83,114} and Hh pathway members, such as Smo, have become anti-neoplastic therapeutic targets. In contrast, GATA transcription factors are typically poor drug targets¹¹⁵. Thus, disorders driven by interactions between GATA and Hh signaling could potentially be treated by targeting Hh pathway members, such as Smo. Considering that PSC ablation also leads to loss of Ush expression, the possibility remains that additional extrinsic signaling pathways also regulate Ush expression. For example, we recently showed that over-expression of the NF κ B homolog, Dorsal, in the PSC reduced Ush expression in the MZ and CZ⁴⁷. Thus, our *in vivo* screen that identified Smo, and by extension Hh signaling, as Ush regulators may identify additional conserved signaling pathways that interface with GATA:FOG complexes to control mammalian hematopoiesis.

In conclusion, our findings support the original hypothesis that the PSC functions as a hematopoietic niche^{40,41}, thereby affirming the use of this larval signaling tissue as a tool to investigate the mechanisms by which the microenvironment maintains progenitors in a multipotent state. Notably, we have delineated PSC-dependent and PSC-independent subpopulations of prohemocytes. Further characterization of these functional subpopulations may increase our knowledge of how hematopoietic progenitors can be regulated by either intrinsic or extrinsic mechanisms. Toward this goal, our findings describe a connection between a major signal transduction pathway and a hematopoietic master regulator that maintains a prohemocyte subpopulation, illustrating how extrinsic signals interface with the intrinsic progenitor regulatory machinery to regulate hematopoiesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by Public Health Service grant DK072229 from the National Institutes of Health. We gratefully acknowledge our colleagues for providing fly strains and antibodies. T. Tokusumi and R. A. Schulz

provided *Tep4-Gal4, hhF4f;Antp-Gal4/TM6B Tb*, *Col-Gal4/CyO GFP* and *MSNF9mo-DsRed(MSN-C)*, S. Govind provided *UAS-GFP;DomeMESO-GFP;Antp-Gal4, TM6B Tb*, from M. Crozatier provided *Domeless-Gal4* and anti-Collier, Xiaoyan Zheng provided *UAS-hh*, M. P. Zeidler and J. C. Hombria provided, *w{w⁺, Dome-MESO}BNI*, J. Skeath provided anti-Odd- skipped, I. Ando provided anti-Nimrod (P1) and mouse anti-Attila (L1), F. C. Kafatos provided anti prophenoloxidase A1.

References

- (1). Crozatier M, Vincent A. *Drosophila*: a model for studying genetic and molecular aspects of haematopoiesis and associated leukaemias. *Dis Model Mech*. 2011;4:439–445.21669932
- (2). Gold KS, Bruckner K. Macrophages and cellular immunity in *Drosophila melanogaster*. *Semin Immunol*. 2015;27:357–368.27117654
- (3). Letoumeau M, Lapraz F, Sharma A *Drosophila* hematopoiesis under normal conditions and in response to immune stress. *FEBS Lett* 2016;590:4034–4051.27455465
- (4). Makhijani K, Bruckner K. Of blood cells and the nervous system: hematopoiesis in the *Drosophila* larva. *Fly (Austin)*. 2012;6:254–260.23022764
- (5). Parsons B, Foley E. Cellular immune defenses of *Drosophila melanogaster*. *Dev Comp Immunol*. 2016;58:95–101.26748247
- (6). Wang L, Kounatidis I, Ligoxygakis P. *Drosophila* as a model to study the role of blood cells in inflammation, innate immunity and cancer. *Front Cell Infect Microbiol*. 2014;3:113.24409421
- (7). Fossett N Signal transduction pathways, intrinsic regulators, and the control of cell fate choice. *Biochim Biophys Acta*. 2013;1830:2375–2384.22705942
- (8). Crozatier M, Meister M. *Drosophila* haematopoiesis. *Cell Microbiol*. 2007;9:1117–1126.17394559
- (9). Evans IR, Wood W. *Drosophila* blood cell chemotaxis. *Curr Opin Cell Biol*. 2014;30:1–8.24799191
- (10). Hartenstein V Blood cells and blood cell development in the animal kingdom. *Annu Rev Cell Dev Biol*. 2006;22:677–712.16824014
- (11). Honti V, Csordas G, Kurucz E, Markus R, Ando I. The cell-mediated immunity of *Drosophila melanogaster*: Hemocyte lineages, immune compartments, microanatomy and regulation. *Dev Comp Immunol*. 2014;42:47–56.23800719
- (12). Kurucz E, Vaczi B, Markus R Definition of *Drosophila* hemocyte subsets by cell-type specific antigens. *Acta Biol Hung*. 2007;58 Suppl:95–111.18297797
- (13). Lavine MD, Strand MR. Insect hemocytes and their role in immunity. *Insect Biochem Mol Biol*. 2002;32:1295–1309.12225920
- (14). Makhijani K, Alexander B, Rao D Regulation of *Drosophila* hematopoietic sites by Activin-beta from active sensory neurons. *Nat Commun*. 2017;8:15990.28748922
- (15). Markus R, Laurinyecz B, Kurucz E Sessile hemocytes as a hematopoietic compartment in *Drosophila melanogaster*. *Proc Natl Acad Sci U S A*. 2009;106:4805–4809.19261847
- (16). Meister M, Lagueux M. *Drosophila* blood cells. *Cell Microbiol*. 2003;5:573–580.12925127
- (17). Dearolf CR. Fruit fly “leukemia”. *Biochim Biophys Acta*. 1998;1377:M13-M23.9540809
- (18). Lanot R, Zachary D, Holder F, Meister M. Postembryonic hematopoiesis in *Drosophila*. *Dev Biol* 2001;230:243–257.11161576
- (19). Rizki TM, Rizki RM. Lamellocyte differentiation in *Drosophila* larvae parasitized by *Leptopilina*. *Dev Comp Immunol*. 1992;16:103–110.1499832
- (20). Owusu-Ansah E, Banerjee U. Reactive oxygen species prime *Drosophila* haematopoietic progenitors for differentiation. *Nature*. 2009;461:537–541.19727075
- (21). Gueguen G, Kalamarz ME, Ramroop J, Uribe J, Govind S. Polydnal viral ankyrin proteins aid parasitic wasp survival by coordinate and selective inhibition of hematopoietic and immune NF-kappa B signaling in insect hosts. *PLoS Pathog*. 2013;9:e1003580.24009508
- (22). Sorrentino RP, Carton Y, Govind S. Cellular immune response to parasite infection in the *Drosophila* lymph gland is developmentally regulated. *Dev Biol*. 2002;243:65–80.11846478
- (23). Babcock DT, Brock AR, Fish GS Circulating blood cells function as a surveillance system for damaged tissue in *Drosophila* larvae. *Proc Natl Acad Sci U S A*. 2008;105:10017–10022.18632567

- (24). Crozatier M, Ubeda JM, Vincent A, Meister M. Cellular immune response to parasitization in *Drosophila* requires the EBF orthologue collier. *PLoS Biol.* 2004;2:E196.15314643
- (25). Dragojlovic-Munther M, Martinez-Agosto JA. Multifaceted roles of PTEN and TSC orchestrate growth and differentiation of *Drosophila* blood progenitors. *Development.* 2012;139:3752–3763.22951642
- (26). Frandsen JL, Gunn B, Muratoglu S, Fossett N, Newfeld SJ. Salmonella pathogenesis reveals that BMP signaling regulates blood cell homeostasis and immune responses in *Drosophila*. *Proc Natl Acad Sci U S A.* 2008;105:14952–14957.18815369
- (27). Gold KS, Bruckner K. Macrophages and cellular immunity in *Drosophila melanogaster*. *Semin Immunol.* 2015;27:357–368.27117654
- (28). Krzemien J, Crozatier M, Vincent A. Ontogeny of the *Drosophila* larval hematopoietic organ, hemocyte homeostasis and the dedicated cellular immune response to parasitism. *Int J Dev Biol.* 2010;54:1117–1125.20711989
- (29). Lebestky T, Chang T, Hartenstein V, Banerjee U. Specification of *Drosophila* hematopoietic lineage by conserved transcription factors. *Science.* 2000;288:146–149.10753120
- (30). Lebestky T, Jung SH, Banerjee U. A Serrate-expressing signaling center controls *Drosophila* hematopoiesis. *Genes Dev.* 2003;17:348–353.12569125
- (31). Louradour I, Sharma A, Morin-Poulard I Reactive oxygen species-dependent Toll/NF-kappaB activation in the *Drosophila* hematopoietic niche confers resistance to wasp parasitism. *Elife.* 2017;6.
- (32). Markus R, Kurucz E, Rus F, Ando I. Sterile wounding is a minimal and sufficient trigger for a cellular immune response in *Drosophila melanogaster*. *Immunol Lett.* 2005;101:108–111.15964636
- (33). Ratheesh A, Belyaeva V, Siekhaus DE. *Drosophila* immune cell migration and adhesion during embryonic development and larval immune responses. *Curr Opin Cell Biol.* 2015;36:71–79.26210104
- (34). RIZKI MT, Rizki RM. Functional significance of the crystal cells in the larva of *Drosophila melanogaster*. *J Biophys Biochem Cytol.* 1959;5:235–240.13654442
- (35). Rizki TM, Rizki RM. Parasitoid-induced cellular immune deficiency in *Drosophila*. *Ann N Y Acad Sci.* 1994;712:178–194.7910721
- (36). Sampson CJ, Valanne S, Fauvarque MO The RhoGEF Zizimin-related acts in the *Drosophila* cellular immune response via the Rho GTPases Rac2 and Cdc42. *Dev Comp Immunol.* 2012;38:160–168.22634526
- (37). Shim J, Mukherjee T, Banerjee U. Direct sensing of systemic and nutritional signals by haematopoietic progenitors in *Drosophila*. *Nat Cell Biol.* 2012;14:394–400.22407365
- (38). Ulvila J, Vanha-aho LM, Ramet M. *Drosophila* phagocytosis - still many unknowns under the surface. *APMIS.* 2011;119:651–662.21917002
- (39). Vlisidou I, Wood W. *Drosophila* blood cells and their role in immune responses. *FEBS J.* 2015;282:1368–1382.25688716
- (40). Krzemien J, Dubois L, Makki R Control of blood cell homeostasis in *Drosophila* larvae by the posterior signalling centre. *Nature.* 2007;446:325–328.17361184
- (41). Mandal L, Martinez-Agosto JA, Evans CJ, Hartenstein V, Banerjee U. A Hedgehog- and Antennapedia-dependent niche maintains *Drosophila* haematopoietic precursors. *Nature.* 2007;446:320–324.17361183
- (42). Benmimoun B, Polesello C, Waltzer L, Haenlin M. Dual role for Insulin/TOR signaling in the control of hematopoietic progenitor maintenance in *Drosophila*. *Development.* 2012;139:1713–1717.22510984
- (43). Benmimoun B, Polesello C, Haenlin M, Waltzer L. The EBF transcription factor Collier directly promotes *Drosophila* blood cell progenitor maintenance independently of the niche. *Proc Natl Acad Sci U S A.* 2015;112:9052–9057.26150488
- (44). Chiu H, Ring BC, Sorrentino RP dUbc9 negatively regulates the Toll-NF-kappa B pathways in larval hematopoiesis and drosomycin activation in *Drosophila*. *Dev Biol.* 2005;288:60–72.16248995

- (45). Dey NS, Ramesh P, Chugh M, Mandal S, Mandal L. Dpp dependent Hematopoietic stem cells give rise to Hh dependent blood progenitors in larval lymph gland of *Drosophila*. *Elife*. 2016;5.
- (46). Ferguson GB, Martinez-Agosto JA. The TEAD family transcription factor Scalloped regulates blood progenitor maintenance and proliferation in *Drosophila* through PDGF/VEGFR receptor (Pvr) signaling. *Dev Biol* 2017;425:21–32.28322737
- (47). Gao H, Baldeosingh R, Wu X, Fossett N. The Friend of GATA Transcriptional Co-Regulator, U-Shaped, Is a Downstream Antagonist of Dorsal-Driven Prohemocyte Differentiation in *Drosophila*. *PLoS One*. 2016;11:e0155372.27163255
- (48). Grigorian M, Liu T, Banerjee U, Hartenstein V. The proteoglycan Trol controls the architecture of the extracellular matrix and balances proliferation and differentiation of blood progenitors in the *Drosophila* lymph gland. *Dev Biol* 2013;384:301–312.23510717
- (49). Grigorian M, DeBruhl H, Lipsick JS. The role of variant histone H2AV in *Drosophila melanogaster* larval hematopoiesis. *Development*. 2017;144:1441–1449.28242611
- (50). Jung SH, Evans CJ, Uemura C, Banerjee U. The *Drosophila* lymph gland as a developmental model of hematopoiesis. *Development*. 2005;132:2521–2533.15857916
- (51). Khadilkar RJ, Rodrigues D, Mote RD ARF1-GTP regulates Asrij to provide endocytic control of *Drosophila* blood cell homeostasis. *Proc Natl Acad Sci U S A*. 2014;111:4898–4903.24707047
- (52). Kulkarni V, Khadilkar RJ, Magadi SS, Inamdar MS. Asrij maintains the stem cell niche and controls differentiation during *Drosophila* lymph gland hematopoiesis. *PLoS One*. 2011;6:e27667.22110713
- (53). Lam V, Tokusumi T, Tokusumi Y, Schulz RA. bantam miRNA is important for *Drosophila* blood cell homeostasis and a regulator of proliferation in the hematopoietic progenitor niche. *Biochem Biophys Res Commun*. 2014;453:467–472.25280996
- (54). Mandal L, Banerjee U, Hartenstein V. Evidence for a fruit fly hemangioblast and similarities between lymph-gland hematopoiesis in fruit fly and mammal aorta-gonadal-mesonephros mesoderm. *Nat Genet*. 2004;36:1019–1023.15286786
- (55). Minakhina S, Druzhinina M, Steward R. Zfrp8, the *Drosophila* ortholog of PDCD2, functions in lymph gland development and controls cell proliferation. *Development*. 2007;134:2387–2396.17522156
- (56). Mondal BC, Shim J, Evans CJ, Banerjee U. Pvr expression regulators in equilibrium signal control and maintenance of *Drosophila* blood progenitors. *Elife*. 2014;3:e03626.25201876
- (57). Morin-Poulard I, Sharma A, Louradour I Vascular control of the *Drosophila* haematopoietic microenvironment by Slit/Robo signalling. *Nat Commun*. 2016;7:11634.27193394
- (58). Oyallon J, Vanzo N, Krzemien J Two Independent Functions of Collier/Early B Cell Factor in the Control of *Drosophila* Blood Cell Homeostasis. *PLoS One*. 2016;11:e0148978.26866694
- (59). Sinenko SA, Mandal L, Martinez-Agosto JA, Banerjee U. Dual role of wingless signaling in stem-like hematopoietic precursor maintenance in *Drosophila*. *Dev Cell*. 2009;16:756–763.19460351
- (60). Sinenko SA, Shim J, Banerjee U. Oxidative stress in the haematopoietic niche regulates the cellular immune response in *Drosophila*. *EMBO Rep*. 2012;13:83–89.
- (61). Small C, Ramroop J, Otazo M An unexpected link between notch signaling and ROS in restricting the differentiation of hematopoietic progenitors in *Drosophila*. *Genetics*. 2014;197:471–483.24318532
- (62). Tokusumi T, Tokusumi Y, Hopkins DW Germ line differentiation factor Bag of Marbles is a regulator of hematopoietic progenitor maintenance during *Drosophila* hematopoiesis. *Development*. 2011;138:3879–3884.21813570
- (63). Tokusumi Y, Tokusumi T, Stoller-Conrad J, Schulz RA. Serpent, suppressor of hairless and U-shaped are crucial regulators of hedgehog niche expression and prohemocyte maintenance during *Drosophila* larval hematopoiesis. *Development*. 2010;137:3561–3568.20876645
- (64). Tokusumi Y, Tokusumi T, Shoue DA, Schulz RA. Gene regulatory networks controlling hematopoietic progenitor niche cell production and differentiation in the *Drosophila* lymph gland. *PLoS One*. 2012;7:e41604.22911822
- (65). Yu S, Luo F, Jin LH. The *Drosophila* lymph gland is an ideal model for studying hematopoiesis. *Dev Comp Immunol*. 2017.

- (66). Leitao AB, Sucena E. *Drosophila* sessile hemocyte clusters are true hematopoietic tissues that regulate larval blood cell differentiation. *Elife*. 2015;4.
- (67). Petraki S, Alexander B, Bruckner K. Assaying Blood Cell Populations of the *Drosophila melanogaster* Larva. *J Vis Exp*. 2015.
- (68). Small C, Paddibhatla I, Rajwani R, Govind S. An introduction to parasitic wasps of *Drosophila* and the antiparasite immune response. *J Vis Exp*. 2012;e3347.22588641
- (69). Williams MJ, Wiklund ML, Wikman S, Hultmark D. Rac1 signalling in the *Drosophila* larval cellular immune response. *J Cell Sci*. 2006;119:2015–2024.16621891
- (70). Williams MJ, Habayeb MS, Hultmark D. Reciprocal regulation of Rac1 and Rho1 in *Drosophila* circulating immune surveillance cells. *J Cell Sci*. 2007;120:502–511.17227793
- (71). Makhijani K, Alexander B, Tanaka T, Rulifson E, Bruckner K. The peripheral nervous system supports blood cell homing and survival in the *Drosophila* larva. *Development*. 2011;138:5379–5391.22071105
- (72). Evans CJ, Hartenstein V, Banerjee U. Thicker than blood: conserved mechanisms in *Drosophila* and vertebrate hematopoiesis. *Dev Cell*. 2003;5:673–690.14602069
- (73). Holz A, Bossinger B, Strasser T, Janning W, Klapper R. The two origins of hemocytes in *Drosophila*. *Development*. 2003;130:4955–4962.12930778
- (74). Honti V, Csordas G, Markus R Cell lineage tracing reveals the plasticity of the hemocyte lineages and of the hematopoietic compartments in *Drosophila melanogaster*. *Mol Immunol*. 2010;47:1997–2004.20483458
- (75). Martinez-Agosto JA, Mikkola HK, Hartenstein V, Banerjee U. The hematopoietic stem cell and its niche: a comparative view. *Genes Dev*. 2007;21:3044–3060.18056420
- (76). Qiu P, Pan PC, Govind S. A role for the *Drosophila* Toll/Cactus pathway in larval hematopoiesis. *Development*. 1998;125:1909–1920.9550723
- (77). Gao H, Wu X, Simon L, Fossett N. Antioxidants maintain e-cadherin levels to limit *Drosophila* prohemocyte differentiation. *PLoS One*. 2014;9:e107768.25226030
- (78). Mondal BC, Mukherjee T, Mandal L Interaction between differentiating cell- and niche-derived signals in hematopoietic progenitor maintenance. *Cell*. 2011;147:1589–1600.22196733
- (79). Crozatier M, Ubeda JM, Vincent A, Meister M. Cellular immune response to parasitization in *Drosophila* requires the EBF orthologue *collier*. *PLoS Biol*. 2004;2:E196.15314643
- (80). Minakhina S, Steward R. Hematopoietic stem cells in *Drosophila*. *Development*. 2010;137:27–31.20023157
- (81). Pennetier D, Oyallon J, Morin-Poulard I Size control of the *Drosophila* hematopoietic niche by bone morphogenetic protein signaling reveals parallels with mammals. *Proc Natl Acad Sci U S A*. 2012;109:3389–3394.22331866
- (82). Tokusumi T, Tokusumi Y, Schulz RA. The mir-7 and bag of marbles genes regulate Hedgehog pathway signaling in blood cell progenitors in *Drosophila* larval lymph glands. *Genesis*. 2018.
- (83). Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev*. 2001;15:3059–3087.11731473
- (84). Lim Y, Matsui W. Hedgehog signaling in hematopoiesis. *Crit Rev Eukaryot Gene Expr*. 2010;20:129–139.21133842
- (85). Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. *Science*. 2004;304:1755–1759.15205520
- (86). Gao H, Wu X, Fossett N. Upregulation of the *Drosophila* Friend of GATA gene U-shaped by JAK/STAT signaling maintains lymph gland prohemocyte potency. *Mol Cell Biol*. 2009;29:6086–6096.19737914
- (87). Amigo JD, Ackermann GE, Cope JJ The role and regulation of friend of GATA-1 (FOG-1) during blood development in the zebrafish. *Blood*. 2009;114:4654–4663.19729519
- (88). Cantor AB, Katz SG, Orkin SH. Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation. *Mol Cell Biol*. 2002;22:4268–4279.12024038
- (89). Cantor AB, Iwasaki H, Arinobu Y Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. *J Exp Med*. 2008;205:611–624.18299398

- (90). Chang AN, Cantor AB, Fujiwara Y GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. *Proc Natl Acad Sci U S A.* 2002;99:9237–9242.12077323
- (91). Fossett N, Tevosian SG, Gajewski K The Friend of GATA proteins U-shaped, FOG-1, and FOG-2 function as negative regulators of blood, heart, and eye development in *Drosophila*. *Proc Natl Acad Sci U S A.* 2001;98:7342–7347.11404479
- (92). Gao Z, Huang Z, Olivey HE FOG-1-mediated recruitment of NuRD is required for cell lineage re-enforcement during haematopoiesis. *EMBO J.* 2009.
- (93). Kurata H, Lee HJ, McClanahan T Friend of GATA is expressed in naive Th cells and functions as a repressor of GATA-3-mediated Th2 cell development. *J Immunol.* 2002;168:4538–4545.11971000
- (94). Muratoglu S, Hough B, Mon ST, Fossett N. The GATA factor Serpent cross-regulates lozenge and u-shaped expression during *Drosophila* blood cell development. *Dev Biol.* 2007;311:636–649.17869239
- (95). Querfurth E, Schuster M, Kulesa H Antagonism between C/EBPbeta and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors. *Genes Dev.* 2000;14:2515–2525.11018018
- (96). Tsang AP, Visvader JE, Turner CA FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. *Cell.* 1997;90:109–119.9230307
- (97). Tsang AP, Fujiwara Y, Hom DB, Orkin SH. Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. *Genes Dev.* 1998;12:1176–1188.9553047
- (98). Fossett N, Zhang Q, Gajewski K The multitype zinc-finger protein U-shaped functions in heart cell specification in the *Drosophila* embryo. *Proc Natl Acad Sci U S A.* 2000;97:7348–7353.10861002
- (99). Tokusumi T, Sorrentino RP, Russell M Characterization of a lamellocyte transcriptional enhancer located within the misshapen gene of *Drosophila melanogaster*. *PLoS One* 2009;4:e6429.19641625
- (100). Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development.* 1993;118:401–415.8223268
- (101). Ward EJ, Skeath JB. Characterization of a novel subset of cardiac cells and their progenitors in the *Drosophila* embryo. *Development.* 2000;127:4959–4969.11044409
- (102). Muller HM, Dimopoulos G, Blass C, Kafatos FC. A hemocyte-like cell line established from the malaria vector *Anopheles gambiae* expresses six prophenoloxidase genes. *J Biol Chem.* 1999;274:11727–11735.10206988
- (103). Gao H, Wu X, Fossett N. Odd-skipped maintains prohemocyte potency and blocks blood cell development in *Drosophila*. *gensis, The Journal of Genetics and Development.* 2011.
- (104). Gao H, Wu X, Fossett N. *Drosophila* E-cadherin functions in hematopoietic progenitors to maintain multipotency and block differentiation. *PLoS One* 2013;8:e74684.24040319
- (105). Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. *Nucleic Acids Res.* 2012;40:5819–5831.22492510
- (106). Sorrentino RP, Tokusumi T, Schulz RA. The Friend of GATA protein U-shaped functions as a hematopoietic tumor suppressor in *Drosophila*. *Dev Biol.* 2007;311:311–323.17936744
- (107). Giordani G, Barraco M, Giangrande A The human Smoothed inhibitor PF-04449913 induces exit from quiescence and loss of multipotent *Drosophila* hematopoietic progenitor cells. *Oncotarget.* 2016.
- (108). Kalamarz M, Paddibhatla I, Nadar C, Govind S. Sumoylation is tumor-suppressive and confers proliferative quiescence to hematopoietic progenitors in *Drosophila melanogaster* larvae. *Biology Open.* 2012;1:161–172.23213407
- (109). Goodrich LV, Johnson RL, Milenkovic L, McMahon JA, Scott MP. Conservation of the hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog. *Genes Dev.* 1996;10:301–312.8595881

- (110). Guibentif C, Gottgens B. Blood: Education for stem cells. *Nature*. 2017;545:415–417.28514445
- (111). Lis R, Karrasch CC, Poulos MG Conversion of adult endothelium to immunocompetent haematopoietic stem cells. *Nature*. 2017;545:439–445.28514438
- (112). Sugimura R, Jha DK, Han A Haematopoietic stem and progenitor cells from human pluripotent stem cells. *Nature*. 2017;545:432–438.28514439
- (113). Cochrane CR, Szczepny A, Watkins DN, Cain JE. Hedgehog Signaling in the Maintenance of Cancer Stem Cells. *Cancers (Basel)*. 2015;7:1554–1585.26270676
- (114). Xie J, Murone M, Luoh SM Activating Smoothed mutations in sporadic basal-cell carcinoma. *Nature*. 1998;391:90–92.9422511
- (115). Zheng R, Blobel GA. GATA Transcription Factors and Cancer. *Genes Cancer*. 2010; 1:1178–1188.21779441

Highlights:

- The PSC and Hedgehog signaling are required for U-shaped expression
- The progenitor population contains PSC-dependent and PSC-independent prohemocytes
- Hedgehog signaling blocks lamellocyte differentiation
- Revealed a link between intrinsic progenitor regulation and the extrinsic niche




Figure 1. Smo acts with Ush to block lamellocyte differentiation and is required to maintain Ush expression levels.

(A–D) Smo acts with Ush to block lamellocyte (lm) differentiation. Lymph glands from (C) *ush/smo* double heterozygotes had significantly increased numbers of lymph gland lobes with lamellocyte differentiation compared to either (A) *smo* heterozygotes or (B) *ush* heterozygotes. Lamellocytes were detected using the *MSN-C* reporter and are marked with arrows. (D) Histogram showing the results of the statistical analyses. Chi-square test; P value is as shown; *smo* (n=214); *ush* and *ush/smo* (n= 26). (E–G) Loss of Ush function has no effect on Smo expression. Smo expression in (F) *ush^{vx22/r24}* (*ush* hypomorphs) was assessed and compared to (E) wild-type controls (+). (G) Histogram showing the results of the statistical analyses. Student's t-test; error bars show standard deviation; P values are as shown; control and *ush* hypomorphs (n = 15). (H–J) Loss of Smo function (*Smo^{DN}*) significantly reduced Ush levels compared to controls (+). *Tep-Gal4* females were crossed to control (+) males or males that carry *UAS-smo^{DN}*. (J) Histogram showing the results of the statistical analyses. Student's t-test; error bars show standard deviation; P values are as shown; control and *Smo^{DN}* (n=18). White dotted lines delineate the entire lymph gland.

Scale bars: panels A–C, 100 μm ; remaining panels, 50 μm . Panels A–D, late-third instar larvae; panels E–J, mid-third instar larvae.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. Hedgehog signaling maintains Ush expression.

Hh signaling was disrupted by (A,B) knocking down Hh expression in the PSC (Antp>Hh^{RNAi}), (C,D) over-expressing Ptc in the MZ (Tep>Ptc^{GOF}), (E,F) knocking down Ci in the MZ (Tep>Ci^{RNAi}) or (G,H) mis-expressing Ush in the PSC (Col>Ush^{GOF}). This resulted in a significant reduction in Ush expression levels. Arrow marks ectopically expressed Ush in the PSC. (I) Histogram showing that the level of Ush expression is significantly reduced in lymph glands with disrupted Hh signaling. Student's t-test; error bars show standard deviation; P values are as shown; control and Hh^{RNAi} (n=20); control and Ptc^{GOF} (n=20); control and Ci^{RNAi} (n=24); control and Ush^{GOF} (n=22). White dotted lines delineate the entire lymph gland. Scale bars: 50 μ m. Mid-third instar larvae.




Figure 3. Hedgehog signaling blocks blood cell differentiation.

(A–F) Hh signaling was disrupted by using *Antp-Gal4* to drive *UAS-hh^{RNAi}* in the PSC. This resulted in a significant increase in the number of crystal cells and plasmatocytes in mid-third instar larvae. (A,B) Crystal cells are marked with ProPO (PPO) and (D,E) plasmatocytes are marked with PI. (C,F) Histograms showing the results of the statistical analyses. Student's t-test; error bars show standard deviation; P values are as shown; (C) control and Hh^{RNAi} (n=10); (F) control and Hh^{RNAi} (n=12). (G–J) *Col-Gal4* was used to express *UAS-ush* or co-express *UAS-ush;UAS-hh* in the PSC of later third instar larvae. (G,H) Mis-expressing Ush resulted in a significant increase in lamellocyte differentiation, (G–I) which was significantly repressed by co-expressing Ush and Hh. (G–I) Lamellocytes are marked with LI. (J) Histogram showing the results of the statistical analyses. Chi-square

test; P value is as shown; Col-Gal4/+ (n=14); Col>Ush (n= 15); Col>Ush;Hh (n=15). Lymph glands are counterstained with Dapi. Scale bars: 50 μ m.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Ush is required to maintain the number of Odd-positive prohemocytes and the level of E-cadherin expression.

Knockdown of Ush expression in the MZ (Tep> Ush^{RNAi}) significantly reduced (A–C) the percentage of Odd-positive prohemocytes and (D–F) the E-cadherin (Ecad) expression domain compared to controls. (C,F) Histograms showing the results of the statistical analyses. Student's t-test; error bars show standard deviation; P values are as shown; (C) control and Ush knockdown (n=12); (F) control and Ush knockdown (n=10). Lymph glands are counterstained with Dapi. White dotted lines delineate the entire lymph gland; yellow dotted line delineates the Ecad-positive prohemocyte pool. Scale bars: 50 μm . Mid-third instar larvae.




Figure 5. Hedgehog signaling maintains the Odd-positive and DomeMESO-positive but not Col-positive prohemocyte population.

(A–G) Disrupted Hh signaling significantly reduced the percentage of Odd-positive prohemocytes compared to controls. Hh signaling was disrupted by (A–D) reducing Hh expression in the PSC (Antp>Hh^{RNAi} or Col>Ush^{GOF}) or (E,F) loss of Ci function in the MZ (Tep>Ci^{RNAi}). (H–J) Knockdown of Hh expression in the PSC resulted in a significant reduction in the number of DomeMESO-GFP expressing prohemocytes. (K–M) Disrupting Hh signaling by mis-expressing Ush in the PSC (Col>Ush^{GOF}) significantly reduced DomeMESO-βgal expression levels. (N–P) Knockdown of Hh expression in the PSC did not significantly reduce the number of Col-positive prohemocytes. (G,J,M,P) Histograms show the results of the statistical analyses. Student's t-test; error bars show standard deviation; P values are as shown; (G) control and Hh^{RNAi} (n=11), control and Ush^{GOF} (n=10), control and Ci^{RNAi} (n=10); (J) control and Hh^{RNAi} (n=11); (M) control and Ush^{GOF} (n=12); (P) control and Hh^{RNAi} (n=11). Mid-third instar lymph glands are counterstained with Dapi. Scale bars: 50 μm.




Figure 6. The PSC maintains a subpopulation of prohemocytes.

Ablation of the PSC (Col>Rpr) results in a significant reduction in (A–C) the level of Ush expression, (D–F) the percentage of Odd-positive prohemocytes, (G–I) the E-cadherin (Ecad) expression domain, (I–?) the percentage of DomeMESO-GFP-positive prohemocytes, but not (M–O) the percentage of Col-positive cells. (C,F,I,L,O) Histograms show the results of the statistical analyses. Student's t-test; error bars show standard deviation; P values are as shown; (C) control and Rpr (n=16); (F) control and Rpr (n=10); (I) control and Rpr (n=16); (L) control and Rpr (n=12); (O) control and Rpr (n=10). (D,E,J,K,M,N) Lymph glands are counterstained with Dapi. White dotted lines delineate the entire lymph gland; yellow dotted line delineates the Ecad-positive prohemocyte pool. Scale bars: 50 μm . Mid-third instar larvae.




Figure 7. The PSC is required to maintain the complement of Odd-positive, but not Col-positive prohemocytes.

Ablation of the PSC (Col>Rpr) results in a significant reduction in the percentage of Odd-positive prohemocytes, but not the percentage of Col-positive cells. (A-A''') Controls and (B-B''') Col>Rpr. A,A',B,B') Lymph glands showing Col and Odd expression, (A, A') PSC marked with yellow arrows, (A,B) counterstained with Dapi, (A'',B'') lymph glands showing only Col expression, (A''', B''') lymph glands showing only Odd expression. (A'-A''') Insets showing cells that express Odd but not Col, marked with arrow. (B'-B''') Insets showing cells with predominantly Col expression but with reduced Odd expression, marked with arrow. (C) Histogram showing that Odd-positive prohemocytes are significantly reduced in response to PSC ablation; whereas Col-positive prohemocytes are not significantly reduced in response to PSC ablation. Black connecting lines compare percentage of Odd control and

experimental samples or Col control and experimental samples. Red connecting line compares percentage of Odd-positive cells in PSC ablated lymph glands with Col-positive cells in control lymph glands. Student's t-test; error bars show standard deviation; P values are as shown; control and Rpr (n=10). White dotted lines delineate the entire lymph gland. Scale bars: 50 μ m. Mid-third instar larvae.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript